There were 360 call-in lines opened for the first of the Scientific Liaison Coalition (SLC) Animal Models of Disease for Toxicity Prediction webinar series, which was presented on Tuesday, May 17 by Diann Blanset, Boehringer Ingelheim. The recording of The Use of Animal Models of Disease in Safety Assessments webinar is posted on the SLC website.
In her webinar presentation, Dr. Blanset reviewed the use of animal models of disease in the evaluation of exaggerated pharmacology and toxicity to improve the relevance and extrapolation of the assessments to the intended disease population. The basic principles of the use of animal models of disease is reviewed as well as the advantages and disadvantages of these models. In addition, specific examples of the use of these models in safety assessments are presented.
The next webinar in this series will be presented on Tuesday, May 31 by Sruthri King, PhD, Pharmacology/Toxicology Team Leader in the Division of Clinical Review in the Office of Generic Drugs within the Center for Drug Evaluation and Research at the US Food and Drug Administration (CDER/FDA). The topic is the Regulatory Perspective on the Use of Animal Models of Disease in Drug Development. The webinar will be held from 11:00 am–12:30 pm ET USA. This live webinar is open only to members of the partnering societies of the SLC listed on the SLC website, and you must register to attend.
The mission of the SLC is to serve as “A partnership of scientific societies with the goal of improving public health through a collaborative interdisciplinary approach.” For more information on the SLC, please contact Marcia Lawson.